Clinical Trial

Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 1, 2023 (before its estimated August 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this single-arm, prospective study is to test in low-burden B-cell lymphoblastic leukemia (B-ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • The efficacy and safety of short-term blinatumomab as a bridging therapy to allo-HSCT in patients with low-burden B-ALL. Participants will take intravenous blinatumomab prior to allo-HSCT with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day and continued for 5 to 10 days. Dexamethasone 20mg was administered 1 hour before the onset of blinatumomab infusion.
Trial Details
NCT Number NCT06111625
Lead Sponsor Sichuan University
Conditions Leukemia, Lymphoid
Enrollment 20 participants
Start Date 2023-09-10
Primary Completion 2024-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-01